Literature DB >> 7642226

Early-appearing tumour-infiltrating natural killer cells play a crucial role in the generation of anti-tumour T lymphocytes.

S Kurosawa1, M Harada, G Matsuzaki, Y Shinomiya, H Terao, N Kobayashi, K Nomoto.   

Abstract

Natural killer (NK) cells that infiltrated into the primary tumour site at an early stage of tumour development, were examined for their participation in the generation of anti-tumour cytotoxic T lymphocytes (CTL). NK cells, which were detected by anti-NK1.1 monoclonal antibody (mAb), increased in the peritoneal exudate cells (PEC) on days 3 and 7 after an intraperitoneal (i.p.) inoculation of syngeneic B16 melanoma cells. These tumour-infiltrating NK cells showed a high level of cytotoxic activity against NK-sensitive YAC-1 cells and an increased expression of interferon-gamma (IFN-gamma) mRNA and interleukin-2 (IL-2) mRNA. The in vivo depletion of NK cells with anti-NK1.1 mAb, prior to i.p. inoculation of B16 melanoma cells, resulted in an increased number of tumour cells in the PEC compared to NK cell non-depleted mice. Interestingly, the differences in tumour cell number between both groups were more prominent on days 7 and 14 than on day 3, which strongly suggested that early-infiltrating NK cells have a large influence on the subsequent anti-tumour response. The in vivo depletion of NK cells prior to immunization with melanoma cells abrogated the capacity of the spleen cells to generate CD8+ tumour-specific CTL after in vitro restimulation. This inability of generating anti-tumour CTL was partially restored by additional i.p. injections of recombinant IL-2 and/or IFN-gamma simultaneously with the immunization of melanoma cells. The in vitro depletion of NK cells prior to the in vitro restimulation with melanoma cells partially impaired the anti-tumour CTL generation from the spleen cells of the immunized mice. Lastly, the in vivo depletion of NK cells prior to immunization with melanoma cells abolished the protective immunity against melanoma cells at the rechallenge. Overall, these results indicate that early-appearing tumour-infiltrating NK cells not only participate in the anti-tumour early defence by themselves, but also play a crucial role in the generation of anti-tumour CTL.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7642226      PMCID: PMC1383901     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

1.  Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL.

Authors:  D E Kern; J P Klarnet; M C Jensen; P D Greenberg
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Synergistic defense system by cooperative natural effectors against metastasis of B16 melanoma cells in H-2-associated control: different behavior of H-2+ and H-2- cells in metastatic processes.

Authors:  Y Kawano; K Taniguchi; A Toshitani; K Nomoto
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

Review 4.  Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.

Authors:  S A Rosenberg; M T Lotze
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

5.  Effects of a cloned cell line with NK activity on bone marrow transplants, tumour development and metastasis in vivo.

Authors:  J F Warner; G Dennert
Journal:  Nature       Date:  1982-11-04       Impact factor: 49.962

6.  One-signal requirement for interferon-gamma production by human large granular lymphocytes.

Authors:  H A Young; J R Ortaldo
Journal:  J Immunol       Date:  1987-08-01       Impact factor: 5.422

7.  Capacity of human large granular lymphocytes (LGL) to produce multiple lymphokines: interleukin 2, interferon, and colony stimulating factor.

Authors:  T Kasahara; J Y Djeu; S F Dougherty; J J Oppenheim
Journal:  J Immunol       Date:  1983-11       Impact factor: 5.422

8.  Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity.

Authors:  W E Seaman; M Sleisenger; E Eriksson; G C Koo
Journal:  J Immunol       Date:  1987-06-15       Impact factor: 5.422

9.  Mechanism of NK activation by OK-432 (Streptococcus pyogenes). I. Spontaneous release of NKCF and augmentation of NKCF production following stimulation with NK target cells.

Authors:  B Bonavida; J Katz; T Hoshino
Journal:  Cell Immunol       Date:  1986-10-01       Impact factor: 4.868

10.  Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.

Authors:  K Itoh; C D Platsoucas; C M Balch
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

View more
  14 in total

Review 1.  Anesthetics, immune cells, and immune responses.

Authors:  Shin Kurosawa; Masato Kato
Journal:  J Anesth       Date:  2008-08-07       Impact factor: 2.078

Review 2.  Regulation of adaptive immunity by natural killer cells.

Authors:  F J Kos
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

3.  A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice.

Authors:  B Hardy; R Kovjazin; A Raiter; N Ganor; A Novogrodsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

4.  Activation of IRF3 contributes to IFN-γ and ISG54 expression during the immune responses to B16F10 tumor growth.

Authors:  Zachary Guinn; Deborah M Brown; Thomas M Petro
Journal:  Int Immunopharmacol       Date:  2017-06-23       Impact factor: 4.932

5.  Antimetastatic effect of NK1+ T cells on experimental haematogenous tumour metastases in the liver and lungs of mice.

Authors:  S Seki; W Hashimoto; K Ogasawara; M Satoh; H Watanabe; Y Habu; H Hiraide; K Takeda
Journal:  Immunology       Date:  1997-12       Impact factor: 7.397

6.  The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.

Authors:  Gregory B Lesinski; Mirela Anghelina; Jason Zimmerer; Timothy Bakalakos; Brian Badgwell; Robin Parihar; Yan Hu; Brian Becknell; Gerard Abood; Abhik Ray Chaudhury; Cynthia Magro; Joan Durbin; William E Carson
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

7.  Inhibition of melanoma growth by subcutaneous administration of hTERTC27 viral cocktail in C57BL/6 mice.

Authors:  Longfei Huo; Hong Yao; Xicai Wang; Gee Wan Wong; Hsiang-fu Kung; Marie C Lin
Journal:  PLoS One       Date:  2010-09-13       Impact factor: 3.240

8.  Enhancing NK cell-mediated cytotoxicity to cisplatin-resistant lung cancer cells via MEK/Erk signaling inhibition.

Authors:  Li Yang; MingJing Shen; Li Jun Xu; Xiaodong Yang; Ying Tsai; Peter C Keng; Yuhchyau Chen; Soo Ok Lee
Journal:  Sci Rep       Date:  2017-08-11       Impact factor: 4.379

9.  iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.

Authors:  Frank Cichocki; Ryan Bjordahl; Svetlana Gaidarova; Sajid Mahmood; Ramzey Abujarour; Hongbo Wang; Katie Tuininga; Martin Felices; Zachary B Davis; Laura Bendzick; Raedun Clarke; Laurel Stokely; Paul Rogers; Moyar Ge; Megan Robinson; Betsy Rezner; David L Robbins; Tom T Lee; Dan S Kaufman; Bruce R Blazar; Bahram Valamehr; Jeffrey S Miller
Journal:  Sci Transl Med       Date:  2020-11-04       Impact factor: 17.956

10.  Evaluation of natural killer cell (CD57) as a prognostic marker in oral squamous cell carcinoma: An immunohistochemistry study.

Authors:  Rashmi Agarwal; Minal Chaudhary; Shruti Bohra; Shree Bajaj
Journal:  J Oral Maxillofac Pathol       Date:  2016 May-Aug
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.